Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

ConvaTec Group Plc

Healthcare US CNVVF

2.73USD
0.00(0%)

Last update at 2026-06-19T20:00:00Z

Day Range

2.622.62
LowHigh

52 Week Range

2.633.92
LowHigh

Fundamentals

  • Previous Close 2.73
  • Market Cap5740.23M
  • Volume100
  • P/E Ratio29.22
  • Dividend Yield2.24%
  • EBITDA587.00M
  • Revenue TTM2439.00M
  • Revenue Per Share TTM1.21
  • Gross Profit TTM 1372.00M
  • Diluted EPS TTM0.09

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 235.12M 245.90M 167.40M 81.90M 151.30M
Minority interest - - - - -
Net income 178.89M 190.50M 130.30M 62.90M 117.60M
Selling general administrative 874.00M 195.00M 212.90M 214.90M 285.30M
Selling and marketing expenses - 645.20M 612.50M 575.90M 539.70M
Gross profit 1375.93M 1283.60M 1200.60M 1103.90M 1123.10M
Reconciled depreciation 224.00M 220.80M 214.80M 209.20M 210.60M
Ebit 416.05M 319.40M 240.70M 208.40M 195.10M
Ebitda 645.03M 540.20M 455.50M 417.60M 405.70M
Depreciation and amortization 228.98M 220.80M 214.80M 209.20M 210.60M
Non operating income net other - - - - -
Operating income 416.05M 324.90M 262.70M 207.30M 203.60M
Other operating expenses 2077.19M 1964.30M 1879.70M 1851.40M 1834.70M
Interest expense 71.56M 81.17M 82.64M 64.70M 44.30M
Tax provision 55.00M 56.00M 37.10M 19.00M 33.70M
Interest income 3.00M 4.80M 5.20M 5.50M 0.80M
Net interest income -68.00000M -78.10000M -75.50000M -67.70000M -43.50000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 56.22M 56.00M 37.10M 19.00M 33.70M
Total revenue 2493.24M 2289.20M 2142.40M 2072.50M 2038.30M
Total operating expenses 959.88M 958.70M 937.90M 882.80M 919.50M
Cost of revenue 1117.31M 1005.60M 941.80M 968.60M 915.20M
Total other income expense net -180.93646M -79.00000M -95.30000M -125.40000M -52.30000M
Discontinued operations - - - - -
Net income from continuing ops 175.00M 189.90M 130.30M 62.90M 117.60M
Net income applicable to common shares - - - 62.90M 117.60M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 3787.04M 3515.00M 3713.70M 3592.00M 3674.00M
Intangible assets 647.03M 805.90M 935.00M 924.90M 902.20M
Earning assets - - - - -
Other current assets 10.02M 78.36M 50.76M - 15.10M
Total liab 2266.62M 1826.10M 2021.00M 1982.30M 1979.20M
Total stockholder equity 1520.43M 1688.90M 1692.70M 1609.70M 1694.80M
Deferred long term liab - - - - 1.90M
Other current liab 97.16M 301.70M 352.24M 166.20M 62.20M
Common stock 251.40M 251.24M 251.50M 250.70M 247.00M
Capital stock 251.00M 251.50M 251.50M 250.70M 247.00M
Retained earnings 1308.09M -828.40000M -888.70000M -892.20000M -842.00000M
Other liab - - - 169.00M 136.50M
Good will 1352.16M 1290.20M 1298.80M 1224.60M 1156.30M
Other assets - - - - 56.30M
Cash 75.12M 64.70M 97.60M 143.80M 463.40M
Cash and equivalents - - - - -
Total current liabilities 616.98M 512.30M 536.40M 533.10M 569.20M
Current deferred revenue - - 26.56M - -
Net debt 1539.46M 1136.90M 1214.80M 1156.40M 971.70M
Short term debt 26.04M 22.00M 20.70M 20.30M 164.50M
Short long term debt - - - 0.00000M 144.80M
Short long term debt total 1614.58M 1201.60M 1312.40M 1300.20M 1435.10M
Other stockholder equity 31.05M 164.41M 2279.37M 2251.20M 2289.80M
Property plant equipment - - - 479.80M 450.30M
Total current assets 941.50M 793.30M 870.00M 889.30M 1110.80M
Long term investments - - - - -
Net tangible assets - - - - -361.80000M
Short term investments - - 0.70M - -
Net receivables 439.70M 301.00M 324.84M 364.00M 301.50M
Long term debt 1398.00M 1122.80M 1226.90M 1211.90M 1199.80M
Inventory 416.66M 349.24M 396.10M 336.90M 308.80M
Accounts payable 493.79M 124.90M 136.90M 346.60M 342.50M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -70.11189M 2101.20M 50.53M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 16.52M 39.20M 46.80M 25.50M
Deferred long term asset charges - - - - -
Non current assets total 2845.54M 2721.70M 2843.70M 2702.70M 2563.20M
Capital lease obligations 120.00M 78.80M 85.50M 88.30M 90.50M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00000M -160.80000M -285.70000M -348.30000M -206.50000M
Change to liabilities - - - 40.70M 10.70M
Total cashflows from investing activities -212.62590M -160.80000M -285.70000M -348.30000M -206.50000M
Net borrowings 254.00M -98.00000M 9.40M -149.00000M -114.10000M
Total cash from financing activities -263.73789M -263.80000M -124.00000M -237.10000M -199.90000M
Change to operating activities - - - -3.30000M 6.70M
Net income 178.89M 190.50M 130.30M 62.90M 117.60M
Change in cash 1.70M -32.90000M -46.20000M -319.60000M -102.00000M
Begin period cash flow 73.42M 97.60M 143.80M 463.40M 565.40M
End period cash flow 75.12M 64.70M 97.60M 143.80M 463.40M
Total cash from operating activities 480.45M 396.20M 367.40M 281.70M 305.90M
Issuance of capital stock - - - - -
Depreciation 228.98M 220.80M 198.10M 209.20M 210.60M
Other cashflows from investing activities - 2.70M 0.60M - -
Dividends paid 143.11M 130.20M 113.37M 88.10M 85.80M
Change to inventory -38.84511M 27.50M -50.59017M -36.30000M -19.60000M
Change to account receivables -59.28991M -26.90000M 19.15M -63.60000M -29.40000M
Sale purchase of stock -333.25020M -10.90000M 0.00000M - 0.00000M
Other cashflows from financing activities -47.02303M -24.70000M -20.03297M 693.50M 469.80M
Change to netincome - - - 72.10M 9.30M
Capital expenditures 138.00M 122.10M 129.20M 144.20M 94.10M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -33.73392M 3.30M -22.40000M -62.50000M -31.60000M
Stock based compensation 28.00M 19.80M 14.60M 16.70M 16.40M
Other non cash items 138.00M -38.20000M 46.80M 123.70M 48.00M
Free cash flow 342.45M 274.10M 238.20M 137.50M 211.80M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CNVVF
ConvaTec Group Plc		 - -% 2.73 29.22 15.85 2.35 4.15 3.20 15.14
ISRG
Intuitive Surgical Inc		 -3.83 0.94% 402.95 73.05 61.73 19.15 10.25 18.41 59.92
ESLOF
EssilorLuxottica Société anonyme		 -13.86 6.73% 192.00 44.84 27.62 4.07 2.49 3.71 16.04
ESLOY
Essilor International SA		 -5.56 5.46% 96.36 41.68 27.25 3.94 2.45 3.71 16.04
BDX
Becton Dickinson and Company		 -3.27 2.27% 140.71 25.56 12.48 2.59 1.76 2.89 12.55

Reports Covered

Stock Research & News

View All

Profile

Convatec Group PLC engages in the development, manufacturing, and sale of medical products, services and technologies for the management of chronic conditions in Europe, North America, and internationally. The company offers advanced wound care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, bladder cancer, inflammatory bowel disease, and trauma. In addition, the company offers continence care products and services for people with urinary continence issues related to spinal cord injuries, neurological disease, prostate enlargement or other causes. Further, it provides infusion care solutions comprising disposable infusion sets for diabetes insulin pumps, or for use in continuous infusion treatments for conditions such as Parkinson's disease. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. Convatec Group PLC was founded in 1978 and is headquartered in London, the United Kingdom.

ConvaTec Group Plc

20 Eastbourne Terrace, London, United Kingdom, W2 6LG

Key Executives

Name Title Year Born
Mr. Karim Bitar CEO & Director 1965
Mr. Jonathan P. Mason Group CFO & Director 1964
Mr. Donal Balfe Exec. VP and Chief of Quality & Operations NA
Dr. Divakar Ramakrishnan Ph.D. Exec. VP & Chief Technology Officer NA
Mr. Mark Reynolds Director of Investor Relations NA
Ms. Kate Postans VP of Investor Relations & Corp. Communications NA
Ms. Natalia Kozmina Exec. VP & Chief HR Officer NA
Mr. Christian Hoengaard Sr. VP & GM - USA NA
Ms. Kjersti Grimsrud Biotechnology, M.Sc. Pres & COO of Infusion Care 1961
Mr. Supratim Bose Pres & COO of Global Emerging Markets 1952

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions